Open AccessAssociation of increased basic salivary proline‐rich protein 1 levels in induced sputum with type 2‐high asthma
Author(s) -
Chen Fengjia,
Liang Yuxia,
Zeng Zhimin,
Du Lijuan,
Xu Changyi,
Guo Yubiao,
Xie Canmao
Publication year - 2022
Publication title -
immunity, inflammation and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 18
ISSN - 2050-4527
DOI - 10.1002/iid3.602
Subject(s) - biomarker , sputum , asthma , medicine , eosinophil , immunology , saliva , airway , eosinophil cationic protein , pathology , biology , tuberculosis , biochemistry , surgery
Background The aim of this study is to reveal whether basic salivary proline‐rich protein BstNI subfamily 1 (PRB1) may be used as a diagnostic biomarker for type 2‐high asthma. Methods PRB1 protein levels in the induced sputum of 67 subjects with asthma and 27 controls were determined by an enzyme‐linked immunosorbent assay. Correlation analyses between PRB1 in the induced sputum and airway inflammatory indicators were also performed. Results PRB1 protein levels were significantly upregulated in the induced sputum of asthmatic patients ( p =0.0098) and correlated with clinical eosinophil‐related indicators and type 2 airway inflammation. These results indicate that PRB1 is a promising biomarker for type 2‐high asthma. Conclusions The expression of PRB1 in induced sputum is a potential biomarker for type 2‐high asthma. The results of this study present new insights into the diagnosis and treatment of asthma.